139 articles with Castle Biosciences
DecisionDx-Melanoma Test Independently Improved Identification of High-Risk Patients Compared to AJCC Staging in Stage I-II Cutaneous Melanoma
Posters presented at the Real World Dermatology for Physician Assistants and Nurse Practitioners conference also include data demonstrating test’s clinical utility
New Publication Highlights Significant Impact of DecisionDx-Melanoma Prognostic Test on Clinical Management of Patients with Melanoma
Prospective, multicenter study recently published in SKIN The Journal of Cutaneous Medicine
Independent Study Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management Decisions in Melanoma
New study of 91 patients with cutaneous melanoma is the third recent publication demonstrating that the DecisionDx-Melanoma test impacts one in two clinical management decisions.
The receipt of the New York permit allows patients in that state to benefit from the Company’s DecisionDx®-Melanoma, DecisionDx®-UM and DecisionDx®-PRAME molecular diagnostic tests that provide actionable molecular information to inform patient care decisions.
Two New Studies at the 2018 AAD Annual Meeting Highlight the Clinical Impact and Utilization of the DecisionDx-Melanoma Test for Cutaneous Melanoma
The data will be presented during the 74th Annual Meeting of the American Academy of Dermatology (AAD), held in San Diego, CA from February 16-18.
Castle Biosciences Release: DecisionDx-Melanoma Test for Cutaneous Melanoma Validated in Two Prospective Multicenter Study Cohorts to Provide Guidance for Sentinel Lymph Node Biopsy Recommendations
Castle Biosciences announced the presentation of a study highlighting research on a new clinical use for the DecisionDx-Melanoma gene expression profile test to guide sentinel lymph node biopsy (SLNB) recommendations.
The new test will complement Castle Biosciences’ standard-of-care DecisionDx-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.
He joined Castle Biosciences effective December 4, 2017.
Castle Biosciences Release: New Publication Highlights First Prospective Performance Assessment Of The Decisiondx-Melanoma Gene Expression Profile Test
Castle Biosciences’ DecisionDx-Melanoma Test Performance Demonstrated In Newly Expanded Multicenter Cohort Of 782 Patients
Castle Biosciences’ Uveal Melanoma Test Receives Positive Medicare Local Coverage Determination And Commercial Insurance Positive Coverage Policies
Castle Biosciences Presents Three New Clinical Studies At ASCO 2017 Highlighting The Accuracy And Performance Of The Decisiondx-Melanoma Gene Expression Profile Test For Cutaneous Melanoma
Castle Biosciences Release: Study Demonstrates Significant And Risk-Appropriate Clinical Impact Of DecisionDx-Melanoma Test Results On Patient Management Decisions
Castle Biosciences’ Decisiondx-Melanoma Test Accurately Predicts Metastatic Risk In Patients With Head And Neck Melanoma
Blue Cross Blue Shield Association Evidence Street Issues Positive Assessment Of Castle Biosciences’ Uveal Melanoma Gene Expression Test
Castle Biosciences Release: Study Demonstrates That Decisiondx-Melanoma Test Improves Identification Of High Risk Skin Melanoma When Used With AJCC Outcome Prediction Tool
Castle Biosciences Release: New Laboratory Receives Accreditation From College of American Pathologists
Study Results With Castle Biosciences’ Uveal Melanoma Gene Expression Test Published In Journal Of Oncology